Effect and Distribution of Contrast Medium after Injection into the Anterior Suprachoroidal Space in Ex Vivo Eyes by Seiler, Gabriela et al.
Effect and Distribution of Contrast Medium after
Injection into the Anterior Suprachoroidal Space in
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Paul A. Dayton,3 and Brian C. Gilger2
PURPOSE. To determine the effects and posterior distribution of
injections made into the anterior suprachoroidal space (SCS).
METHODS. The anterior SCS of adult porcine and canine ex vivo
eyes was cannulated. Latex injections and high frequency ul-
trasound (50 MHz) was used to image the effect and distension
of the SCS. Flow characteristics and percentage maximal dis-
tribution of microbubble contrast injection into the SCS were
assessed by 2D and 3D ultrasound.
RESULTS. Mean (SD) distension of the SCS with PBS increased
from 1.57 (0.48) mm after injection of 250 L to 3.28 (0.57)
mm with 1000 L PBS. Eyes injected at physiologic IOP had no
significant difference in SCS distension. In real-time 2D ultra-
sound, the contrast agent flowed from the injection site to the
opposite ventral anterior SCS and the posterior SCS. Contrast
arrived at the opposite and posterior SCS 7.8 (4.6) and 7.7 (4.6)
seconds after injection, respectively. In sagittal images, con-
trast was visible in 24.0%to 27.2% of the SCS; in 10 of 12 eyes,
contrast reached the posterior pole of the eye. In 3D images,
contrast medium occupied 39.0% to 52.1% of the entire SCS.
CONCLUSIONS. These results suggest that the SCS can expand, in
a dose-dependent manner, to accommodate various volumes of
fluid and that it is possible to image the SCS with ultrasound
contrast. The authors’ hypothesis that a single anterior SCS
injection can reach the ocular posterior segment was sup-
ported. Further development of SCS injections for treatment of
the ocular posterior segment is warranted. (Invest Ophthalmol
Vis Sci. 2011;52:5730–5736) DOI:10.1167/iovs.11-7525
Diseases of the posterior segment of the eye are among themost common causes of blindness. In humans, these dis-
eases include age-related macular degeneration, proliferative
vitreoretinopathy, diabetic macular edema, and endophthalmi-
tis. Although there are many advances in the treatment of these
posterior segment diseases, the challenges of drug delivery to
this part of the eye remain high.1 Eye drops continue to be a
mainstay in the treatment of ocular disease, but most topical
medications do not penetrate the posterior segment.2,3 Local
therapy of the eye, such as periocular and intravitreal injec-
tions, has recently become popular to treat ocular disease
because they minimize systemic side effects and take advan-
tage of small tissue volumes and compartments of the eye.4,5
Natural barriers to ocular drug penetration, such as conjuncti-
val lymphatics, sclera, choroidal circulation, and epithelial
tight junctions, limit the ability of periocular injections to reach
posterior target tissues.1,6,7 Instead, ocular posterior segment
disease, such as choroidal neovascularization, macular degen-
eration, and retinal degeneration, are commonly treated locally
by intravitreal or subretinal injections or use of sustained-
release devices. However, these treatment modalities are sub-
ject to complications such as injection site hemorrhage, retinal
detachment, cataract formation, endophthalmitis, elevated in-
traocular pressure, opacities of the visual axis, and local toxic-
ity.8–10 Therefore, alternative sites for drug delivery to the
ocular posterior segment are needed.
Drug delivery to the suprachoroidal space (SCS), a potential
space located between the choroid and the sclera,11 avoids
many of the disadvantages of other local therapies by eluding
barriers such as conjunctival lymphatics and the sclera and may
avoid complications associated with intraocular injections or
implants. Furthermore, because the SCS is adjacent to the
entire choroid and thus the ocular posterior segment, drug
delivery using the SCS has the potential for wide drug distri-
bution and for reach to posterior target tissues.
Recently, studies have demonstrated promise in the use of
the SCS as a site for drug delivery to the eye. Use of the SCS as
a drug delivery site was first described by Einmahl et al.,12 who
placed a poly-ortho ester–sustained drug delivery system in the
SCS in rabbits and demonstrated sustained delivery in the SCS
for 3 weeks.12 Ultrasound was used to track the distribution of
injected material in this study.12 In 2006, Olsen et al.13 de-
scribed the use of a fiberoptic microcannula to access the SCS
in a pig with few complications.13 Sustained ocular drug de-
livery of triamcinolone to the SCS was demonstrated using this
cannula, with resulting low systemic drug levels. A volume of
12 L triamcinolone was placed into the SCS by use of the
flexible catheter, and no side effects were noted with the
cannulation procedure or drug; after the cannula was removed,
the SCS was found to return to a normal configuration.13
Subconjunctival infusion (1 and 10 L/min) of gadolinium-
diethylenetriaminopentaacetic acid (Gd-DTPA) in rabbits re-
sulted in no ocular posterior segment distribution, whereas
anterior intrascleral infusion resulted in rapid entry of Gd-
DTPA into the SCS. The Gd-DTPA was then demonstrated to
widely distribute to the posterior segment of the eye by way of
the SCS.6 In another study in rabbits, up to 100 L fibrin glue
was injected into the SCS, resulting in minimal toxicity and
complications.14 Preliminary studies have also demonstrated
that large biological proteins, such as a human antibody (i.e.,
bevacizumab), injected into in the SCS in a pig model resulted
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in no inflammation, whereas a similar dose injected intravitre-
ally resulted in granulomatous vasculitis and vitreitis.15 Finally,
the effectiveness of drug delivery to the SCS was demonstrated
in a study in which a sustained-release matrix-reservoir cyclo-
sporine device that was placed in the SCS resulted in long-term
control of uveitis in a naturally occurring model of autoim-
mune uveitis.16 Therefore, the SCS route of delivery may offer
a unique avenue for future routine injections that are safe and
effective in targeting retinal and macular diseases.
To further develop the SCS as a site for drug delivery, it is
important to determine whether injections of medications into
the anterior SCS, the most accessible location of the SCS, will
allow distribution of the drug to the posterior targeted tissue.
The SCS can be accessed through a small sclerotomy or by
microneedles placed 4 to 6 mm posterior to the limbus, but the
amount of drug distribution to the ocular posterior segment
that can be achieved from this anterior injection location is not
known. Recently, Patel et al.17 described the use of hollow
microneedles to precisely inject drugs into the SCS. In this
study, volumes up to 35 L prototype drugs of particle sizes up
to 1000 nm were injected into the porcine SCS. These injec-
tions resulted in a 7% distribution to the posterior SCS.17
However, appropriate injection volumes, area of drug distribu-
tion, and effect on the SCS of injections must be further
evaluated. Furthermore, the duration of drug delivery and the
ability of the drug to reach target tissues, especially the retina,
must be determined for each drug and formulation.
The purpose of this study was to evaluate injections into the
anterior SCS to determine the effect and distribution to the
posterior SCS and to determine whether target tissues can be
reached. In this study, injection volumes, acute effects of
injections on the SCS, and flow characteristics of injections in
the SCS were determined.
METHODS
Suprachoroidal Injection Technique
Adult porcine ex vivo eyes (Animal Technologies, Tyler, TX) were
collected and shipped overnight on ice. Canine ex vivo globes were
collected at a local animal shelter immediately after euthanatization
and transported on ice. All globes were used within 24 hours of
collection. Each globe was cleaned of excess periocular tissue, includ-
ing conjunctiva, extraocular muscle, and orbital fat. Canine and por-
cine eyes are similar in size (e.g., canine vitreous humor volume is
approximately 1.7 mL whereas porcine vitreous volume is slightly
higher at 2.0 mL18,19), and, therefore, the procedures described are
applicable to each type of eye. A 2-mm full-thickness scleral incision
was made 5 mm posterior to the superior limbus to expose the SCS. A
27-gauge cannula (Anterior Chamber Cannula; BD Visitec, Waltham,
MA) was placed 1 mm into the SCS through the scleral incision with
the opening of the cannula directed posteriorly. Cyano-acrylate tissue
adhesive (Pacer Technology, Rancho Cucamonga, CA) was used to seal
the sclera incision and fixate the cannula to the external sclera.
Latex Distribution
Porcine and canine eyes were allowed to warm to room temperature
for 30 minutes and then were injected with undiluted liquid anatomic
latex (Carolina Biological Supply Company, Burlington, NC) through
the 27-gauge cannula placed in the SCS. The liquid latex was injected
until injection resistance developed or when disruption of the cyano-
acrylate incision seal and reflux of latex through the scleral incision
occurred. An injection of approximately 1000 L latex was required.
Globes were then fixed in 10% buffered formalin (Fisher Scientific,
Kalamazoo, MI) for 48 hours and sectioned either sagittally or in
quadrants (i.e., flat mount) after removal of the ocular anterior seg-
ment. The retina and choroid were then removed, exposing the latex
in the SCS and the sclera. High-resolution digital photographs (Nikon
D200, AF-S DX Micro NIKKOR 85mm f/3.5G ED VR Lens; Nikon USA
Inc, Melville, NY) of the eyes were analyzed using image analysis
software (Elements 4.0, Adobe Photoshop, San Jose, CA; ImageJ soft-
ware [developed by Wayne Rasband, National Institutes of Health,
Bethesda, MD; available at http://rsb.info.nih.gov/ij/index.html]) to
determine overall percentage area of distribution of latex to the entire
SCS. Results were reported as mean ( SD) of percentage SCS distri-
bution.
SCS Distension
Ex vivo canine and porcine eyes were used for this study. SCS cannu-
lation was performed as described earlier. During the injection of 250,
500, 800, and 1000 L (n  6 eyes for each volume) of 0.9% phos-
phate-buffered saline (Fisher Scientific, Fair Lawn, NJ), high-frequency
(50 MHz) ultrasound (E-technologies, Bettendorf, IA) was used to
image the effect and distension of the injections on the SCS in real
time. The ultrasound probe was positioned immediately over the
injection site so that the adjacent sclera, SCS, and ciliary body/choroid
were imaged in real time during the injection. Images were collected,
and the maximal distance that the SCS was distended when injected
with PBS was measured with internal calipers of the ultrasound. Re-
sults were reported as mean  SD of SCS separation in millimeters of
six eyes at each PBS volume.
To determine the effect of physiologic intraocular pressure (IOP)
on SCS distension after injection and to determine the changes of IOP
after SCS injection, this study was repeated in porcine ex vivo eyes
(n  4 per injection volume). After placement of the catheter in the
SCS as described, a 27-gauge needle was placed through the limbus
into the anterior chamber, and cyano-acrylate tissue adhesive was used
to seal the limbal incision. The needle was connected with 0.9%
saline-filled tubing to a pressure transducer (MedEx LogiCal Trans-
ducer, Model MX960; MedExSupply Medical Supplies, Monsey, NY)
and an electronic monitor, allowing for continuous measurement of
IOP. Immediately before injection of 250, 500, 800, or 1000 L PBS
into the SCS, the IOP was increased to 15 mm Hg by injection of 0.9%
saline through the 27-gauge anterior chamber needle. Maximal disten-
sion of the SCS was measured and reported as described using internal
calipers of the ultrasound. The IOP (in mm Hg) at the time of maximal
SCS distension was recorded for each injection volume and reported as
mean change in IOP (SD) mm Hg.
Two-Dimensional Ultrasound Contrast Imaging
of SCS
Porcine ex vivo eyes were used for this study. Using contrast-enhanced
ultrasound (Mylab70; Biosound Esaote, Inc., Indianapolis, IN), 250,
500, and 800 L microbubble ultrasound contrast agent (Targestar-P,
Targeson Inc., San Diego, CA) was injected into the anterior supracho-
roidal space through 27-gauge cannulas placed as described earlier. In
real time, observations were recorded, including flow characteristics of
the contrast agent in the SCS. Percentage of maximal distribution in the
SCS of contrast agent was determined in the sagittal ultrasound plane
using image analysis software (Elements 4.0 [Adobe Photoshop]; Im-
ageJ 1.42q). Results were reported as mean ( SD) of percentage SCS
distribution of four eyes at each contrast agent volume. Using contrast
medium detection software (Qontrast; Biosound Esaote, Inc., Indianap-
olis, IN), regions of interest were placed over the entire SCS and the
posterior SCS, and contrast enhancement over time was measured as
mean pixel intensity.
Three-Dimensional Ultrasound Contrast Imaging
of SCS
Porcine ex vivo eyes were imaged using a custom 3D contrast imaging
system that interfaces a computer-controlled linear motion axis with a
clinical ultrasound scanner (Acuson Sequoia; Siemens Medical Solu-
tions, Malvern, PA). A 4-MHz (4-C1) transducer and contrast imaging
(Cadence CPS; Siemens Medical Solutions, Malvern, PA) were used.
The porcine eye was placed in a water bath, and 250 L microbubble
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contrast medium was injected through 27-gauge catheters placed into
the anterior SCS. Dynamic contrast medium inflow was observed in a
midsagittal plane, followed by 3D imaging of the entire globe to assess
spatial distribution of the contrast agent. Percentage of maximal dis-
tribution in the SCS of contrast agent was determined slice by slice
using image analysis software (Elements 4.0 [Adobe Photoshop]; Im-
ageJ 1.42q). Results were reported as mean ( SD) of percentage SCS
distribution of 4 eyes.
Statistical Analysis
Statistical analysis of the data was performed using computerized
software (JMP Statistical Discovery Software, vs 8.0; SAS Inc., Cary,
NC). Differences in SCS distension, distribution of latex, distribution of
contrast media, and contrast medium enhancement were analyzed
using analysis of variance (ANOVA) with Tukey’s HSD test. Differences
between species were analyzed using an unpaired t-test. Significance
was set at P  0.05 for all comparisons.
RESULTS
Latex Distribution
Liquid anatomic latex was injected into the anterior SCS to
determine posterior distribution from a single anterior injec-
tion. In canine eyes, latex distributed to a mean ( SD) of
39.9%  5.2% of the entire SCS on sagittal sections (n  4) and
46.8%  13.1% of the entire SCS when the eyes were sectioned
in quadrants (n  4; Fig. 1). In porcine eyes, latex distributed
to a mean ( SD) of 54.8%  15.4% of the SCS in sagittal
sections (n  4) and 42.1%  4.3% of the SCS in eyes sectioned
in quadrants (n  4; Fig. 1). There were no significant differ-
ences between species or sectioning techniques in area of
distribution. Latex reached the SCS adjacent to the area cent-
ralis (i.e., macula) in 9 of 16 (56%) eyes (Fig. 1).
SCS Distension
High-frequency ultrasound was used to image the anterior SCS
during injection with PBS. The metallic tip of the catheter was
visualized in the SCS on the ultrasonic image. On injection, the
SCS rapidly expanded locally, then dissected posteriorly (Fig. 2).
As expected, the lower volumes of injection resulted in less
distension of the SCS. In the canine eyes, maximum mean (
SD) distension of the SCS from injection with 250 L PBS
(1.25  0.07 mm) was significantly lower than the maximum
distension created from 500 L PBS (2.25  0.07 mm; P 
0.02), 800 L PBS (2.25  0.21 mm; P  0.02), and 1000 L
PBS (2.7  0.28 mm; P  0.005; ANOVA with Tukey’s HSD;
Fig. 3). In the porcine eyes, maximum mean ( SD) distension
of the SCS from injection with 250 L PBS (1.57  0.48 mm)
was significantly lower than the maximum distension created
from 800 L PBS (2.98  0.37 mm; P  0.002), and 1000 L
PBS (3.28  0.57 mm; P  0.0002). Furthermore, the mean
distension of the SCS from injection with 500 L PBS
(2.57  0.52 mm) was significantly lower than the mean dis-
tension created from 1000 L PBS (P  0.036; ANOVA with
Tukey’s HSD; Fig. 3). There were no significant differences in
FIGURE 1. Temporal (t) and nasal
(n) sagittal sections of a canine globe
showing the suprachoroidal distribu-
tion of a single injection of blue latex
in color (A) and in the “edges” func-
tion of ImageJ software (B). Canine
globe sectioned in quadrants demon-
strating distribution of blue latex in the
SCS in color (C) and in the “edges” func-
tion of ImageJ software (D).
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distension of the SCS between canine and porcine eyes at any
injection volume except 800 L, at which the distance was
significantly greater in the porcine eye (2.98  0.37 mm) than
in the canine eye (2.25  0.21 mm; P  0.035; Student’s t-test;
Fig. 3).
To determine the effect of physiologic intraocular pressure
(IOP) on SCS distension after injection and to determine the
changes of IOP after SCS injection, this study was repeated in
porcine ex vivo eyes with IOPs of 15 mm Hg. In these eyes,
there was no significant difference in mean ( SD) distension
of the SCS between (eyes injected with 250 L (1.65  0.79
mm), 500 L (2.8  0.69 mm), or 800 L (2.8  0.92 mm; Fig.
3). There also were no significant differences in mean disten-
sion for each injection volume between eyes with IOPs at 15
mm Hg compared with the ex vivo porcine or canine eyes (Fig.
3). However, injections greater than 800 L could not be
completed because of resistance to injection from high IOPs.
In fact, at maximum distension during the injection of 250 L,
IOPs were transiently (10 seconds) elevated a mean ( SD)
of 39.3  16.5 mm Hg; during the 500-L injection, IOP in-
creased a mean ( SD) 189.5  118.1 mm Hg; and during the
800-L injection, IOP increased a mean ( SD) 285.8  42.9
mm Hg.
Two-Dimensional Ultrasound Contrast Imaging of
SCS. After the injection of microbubble ultrasound contrast
agent into the anterior SCS of porcine eyes (n  4 eyes per
volume), contrast was visible initially in the SCS at the injection
site and then at the opposite ventral anterior SCS and the
posterior SCS. This is illustrated in Figure 4, where contrast
enhancement (measured as mean pixel intensity) starts to in-
crease first at the injection site, followed by the opposite
anterior SCS and the posterior SCS. The overall mean ( SD)
time after injection for contrast to appear at the opposite and
posterior SCS was 7.8  4.6 and 7.7  4.6 seconds, respec-
tively. This suggests that the contrast flowed in the SCS initially
parallel to the limbus in the anterior suprachoroidal space as it
extended posteriorly (Fig. 5; Supplementary Movie S1, http://
www.iovs.org/lookup/suppl/doi:10.1167/iovs.11-7525/-/DC
Supplemental). Mean ( SD) time to maximum contrast inten-
sity visible in the SCS on the ultrasound image was 16.2  4.6
seconds after injection. There were no significant differences
among 250-, 500-, and 800-L contrast volumes injected in time
after injection to appearance of the contrast on the ultrasound
image (Table 1). In the sagittal ultrasound section, the micro-
bubble contrast agent was visible in a mean 24.0% to 27.2% of
the entire SCS when injected with 250, 500, or 800 L micro-
bubble contrast agents (Table 1). There were no significant
differences in area of the SCS where contrast agent was visible
among the three volumes injected (P  0.90) or in mean pixel
intensity of contrast medium (P  0.35; Fig. 6). Despite only
approximately 25% of the SCS having visible contrast, 10 of 12
eyes (83.3%) injected had contrast that reached the posterior
pole of the eye (one 250-L and one 800-L injection did not,
but contrast was observed to extend to approximately two-
thirds of the posterior SCS).
Three-Dimensional Ultrasound Contrast Imaging of
SCS. As described for 2D ultrasound imaging, in 3D imaging
(n  4 eyes) microbubble contrast medium first appeared in
FIGURE 2. High-frequency ultrasound
(50 MHz) images demonstrating the dis-
tension of the SCS in porcine eyes after
injection with 250 L (A), 500 L (B),
800 L (C), and 1000 L (D) of PBS.
Left: anterior segment; right: poste-
rior segment. S, sclera; C-R, choroid
and retina.
FIGURE 3. Mean  SD distension of the SCS after injection with PBS
measured using high-frequency (50 MHz) ultrasound of ex vivo por-
cine eyes (porcine; n  6), canine eyes (canine; n  6), and porcine
eyes with IOP at 15 mm Hg (porcine at 15 IOP; n  4). (a) Porcine
eyes; mean ( SD) distension of the SCS from injection with 250 L
PBS was significantly less than the maximum distension created from
800 L PBS (P  0.002) and 1000 L PBS (P  0.0002). (b) Canine
eyes; mean ( SD) distension of the SCS from injection with 250 L
PBS was significantly less than the mean distension created from 500
L PBS (P  0.02), 800 L PBS (P  0.02), and 1000 L PBS (P 
0.005). (c) Porcine eyes; mean distension of the SCS from injection
with 500 L PBS was significantly less than the mean distension
created from 1000 L PBS (P  0.036). (d) Mean distance was signif-
icantly less in the canine eye than in the porcine eye for the 800-L PBS
injection volume (P  0.035; Student’s t-test). There was no significant
difference in mean distension of the SCS in porcine eyes at 15 mm Hg
compared with the other ex vivo eyes at any injection volume.
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the SCS at the injection site, then moved to the opposite side
of the anterior SCS and into the posterior segment. Contrast
agent was uniformly distributed in the anterior SCS, and
reached the posterior SCS in all eyes (Fig. 7; Supplementary
Movie S2, http://www.iovs.org/lookup/suppl/doi:10.1167/
iovs.11-7525/-/DCSupplemental). Median percentage of con-
trast agent distribution in the entire SCS was 45.3%, with a
range of 39.0% to 52.1%.
DISCUSSION
A single injection into the anterior SCS resulted in the distri-
bution of latex to nearly 50% of the ocular posterior segment in
two large animal species commonly used for retinal research.
The SCS was demonstrated to be able to expand, in a dose-
dependent manner, to accommodate various volumes of in-
jected fluid. Physiologic IOP did not affect the distension of the
SCS after injection, but there was a dose-dependent transient
increase in IOP after injection. The clinical and pathologic
significance of this transient increase in IOP must be further
investigated; however, injections of 500 and 800 L in eyes
with physiologic IOP resulted in acute pressure elevations
likely sufficient to damage retinal ganglion cells or the optic
nerve.20,21 The results of this study also demonstrated that it is
possible to image the SCS with an ultrasound contrast agent.
Furthermore, these results support our hypothesis that a single
anterior suprachoroidal injection of a drug with a volume as
low as 250 L can reach the ocular posterior segment in eyes
that approximate the size and volume of the human eye.
Together our results suggest that injections of 250 L or less
can be accommodated by the SCS, result in only transient
relatively modest elevations of IOP, and rapidly extend to a
large percentage of the ocular posterior segment. Therefore,
further development of SCS injections for treatment of macular
disease and other diseases of the posterior segment of the eye
is warranted.
Our results are similar to the results from a recent study of
the injection of particles into the SCS of ex vivo rabbit eyes.
Using specific microneedles, a 15-L volume of microparticles
injected into the anterior SCS resulted in distribution of the
particles to approximately 36% of the total circumference of
the eye.22 However, in porcine ex vivo eyes, 35 L barium
sulfate contrast agent particles resulted in only approximately
7% posterior segment distribution, as determined with recon-
structed MRI images.22 Therefore, higher SCS injection vol-
FIGURE 5. Ultrasound image, with overlay of a basic ocular schematic,
after injection of 500 L microbubble contrast agent into the superoan-
terior SCS of an ex vivo porcine eye. Contrast was visible initially in the
SCS at the injection site (1), then visible at the opposite ventral anterior
SCS (2) and the posterior SCS (3). An ultrasound system with contrast
imaging capabilities was used to image the eyes.
FIGURE 4. Mean pixel intensity representing contrast medium enhancement in regions of interest placed over the injection site, opposite the
anterior SCS and the posterior SCS after the injection of 250, 500, and 800 L microbubble contrast agent into the superoanterior SCS of an ex
vivo porcine eye. Measurements of all contrast medium doses are combined in this graph. Contrast enhancement increases rapidly at the injection
site, followed by the opposite anterior and posterior SCS.
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umes, as used in our studies, may be required for adequate
posterior distribution of medication in larger eyes. What effect
these large injection volumes had on the in vivo eye remains to
be determined. However, it has been demonstrated that the in
vivo rabbit eye can accommodate SCS injections of up to 200
L sodium hyaluronate or perfluorocarbon gases.23,24 There-
fore, it is likely that the larger canine, porcine, or human eye
would also tolerate SCS injection volumes capable of large
(200–250 L) posterior segment distribution.
This study demonstrates that contrast-enhanced ultrasound
can be used to determine the dynamic distribution of a single
anterior SCS injection in real time. Ultrasound contrast agents
are composed of a perfluorocarbon gas core encapsulated by a
lipid shell, stabilized by a layer of polyethylene glycol. The
microbubbles are suspended in saline at a concentration of
approximately 1  109 particles/mL, with a median bubble
diameter of approximately 2.5 m.25 Ultrasound contrast
agents may not accurately reflect the flow and distribution of
drugs in the SCS because of differences in particle size and
viscosity. Microbubbles, because of their gas content, tend to
rise to the upper portion of a fluid-filled space, which could
alter the distribution of the contrast agent in the SCS when
compared with injected medication. However, the porcine
eyes in this study were imaged with the anterior SCS facing up,
which might have led to an increased accumulation of micro-
bubbles in the anterior SCS and a non–gravity-dependent liquid
would be expected to reach the posterior SCS even better. The
fact that the ultrasound contrast agent consistently reached the
posterior segment is very encouraging for the development of
SCS injections for the treatment of ocular posterior segment
diseases.
Contrast flow, when observed dynamically in a midsagittal
image plane, extended from the injection site in the anterior
SCS to the contralateral anterior SCS, indicating flow parallel to
the limbus in the anterior SCS. Simultaneously, or in some eyes
with a small delay, contrast medium also extended to the
posterior SCS. In all eyes the posterior segment was reached by
the contrast agent within seconds, confirming that the SCS can
be used as a site for drug delivery and that injections of
medications into the anterior SCS, the most accessible location
of the SCS, will allow distribution of the drug to the posterior
targeted tissue. Viscous or microparticle formulations may
have different distribution characteristics, but our preliminary
studies with latex, PBS, and ultrasound contrast demonstrated
rapid distribution into the posterior SCS.
The ability of ultrasound contrast agents to reach the pos-
terior segment of the eye is not only of value when considering
the anterior SCS as a site for therapeutic drug administration, it
may also be a method for specific drug delivery. Contrast
ultrasound-assisted drug delivery has been shown to be feasible
both in vivo and in vitro.26 Binding of pharmaceutical agents to
the microbubble shell turns the contrast agent into a vehicle
for drug or gene delivery.27,28 Moreover, a higher energy ul-
trasound beam can be applied focally in the targeted region,
such as the macula, to disrupt microbubbles and cell mem-
branes and locally deliver the drug or gene, thus avoiding the
systemic distribution of the substance and potentially reducing
the blood-ocular barrier.29,30
Three-dimensional contrast-enhanced ultrasound is a novel
technology that allows understanding of the pattern of distri-
FIGURE 6. Mean pixel intensity representing contrast medium en-
hancement in regions of interest placed over the posterior SCS after
the injection of 250, 500, and 800 L microbubble contrast agent into
the superoanterior SCS of an ex vivo porcine eye. No significant
differences in contrast medium enhancement were detected with
different doses (P  0.35).
FIGURE 7. Three-dimensional model of contrast agent distribution
within the eye. Microbubble contrast agent (250 L) was injected into
the superoanterior SCS of an ex vivo porcine eye, and 3D ultrasound
was performed. The contrast agent in the SCS is isolated in this image;
no other structures are displayed. The corneal surface faces up in this
image. Arrow: injection site.











250 L 12.3  5.9 4.3  1.5 24.0  9.3 3/4 eyes
500 L 6.0  4.1 9.5  6.0 24.6  9.2 4/4 eyes
800 L 6.3  2.1 8.5  3.9 27.2  13.2 3/4 eyes
Overall 7.8  4.6 7.7  4.6 25.3  9.8 10/12 eyes
Values are mean  SD.
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bution of contrast medium in the SCS. Selecting a single two-
dimensional image, or even multiple two-dimensional images,
for measuring the percentage distribution of contrast agent is
prone to underestimation or overestimation of the actual dis-
tribution because of the variability of contrast flow within the
SCS.31 This may explain the higher percentage of contrast
medium distribution when considering 3D imaging of the en-
tire eye compared to a single slice; 3D imaging was limited to
the lowest volume of 250 L because no statistically significant
differences in contrast distribution were detected with 2D
imaging performed with different volumes.
These studies represent a novel approach for performing
and assessing injections into the anterior SCS and suggest that
access to the anterior SCS, either by cannula or microneedles,
may allow the distribution of drugs to a large area of the ocular
posterior segment and to the macular area of the eye. Addi-
tional studies are needed to determine the effect of choroidal
blood flow and IOP on the distribution of specific medications
and formulations to the retina and macula. Furthermore, con-
trast ultrasound-assisted drug delivery from SCS injections may
represent a novel, targeted, and less invasive method of treat-
ment of ocular posterior segment disease.
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